Collaboration, technology & innovation in the scale-up of viral vector manufacturing

Cell & Gene Therapy Insights 2022; 8(8), 961–965

DOI: 10.18609/cgti.2022.142

Published: 2 September 2022
Matthias Hebben

Matthias Hebben has been serving as vice president of technology development at LogicBio Therapeutics since February 2019. In his role, he is leading the CMC efforts, including vector core, capsid optimization, process development, analytical development and clinical product manufacturing. Before that, he served as director of technology development and head of bioprocess development at Genethon for 6 years. Before that, he occupied several positions at Vivalis (Valneva), Intervet Shering Plough and Virbac. Matthias has a PhD in molecular biology and a MSc in bioprocess engineering.